Individuals with Down syndrome (DS) have a dramatically increased risk of developing Alzheimer's disease (AD), with nearly all individuals exhibiting AD neuropathology—including amyloid-beta (Aβ) plaques and tau neurofibrillary tangles (NFTs)—by age 40 years. This creates a unique natural model for studying the interaction between amyloid and tau pathology across the human lifespan. The triplication of chromosome 21 leads to overexpression of the amyloid precursor protein (APP) gene, resulting in lifelong overproduction of Aβ peptides that drives early-onset tau pathology[1].
This page provides comprehensive coverage of tau phosphorylation changes in Down syndrome, including neuropathological findings from postmortem studies, fluid biomarker discoveries, and the clinical implications for therapeutic intervention timing.
The amyloid cascade hypothesis posits that Aβ accumulation is the initiating event in AD pathogenesis, leading to downstream tau pathology, synaptic dysfunction, and neuronal loss. In Down syndrome, this cascade is accelerated by genetic dosage effects[2]:
The extra copy of APP results in approximately 1.5-fold overexpression of APP protein throughout the lifespan, creating a chronic state of Aβ overproduction that begins even before birth. This makes DS the earliest-onset form of amyloid pathology known in humans[3].
While amyloid deposition starts early in DS, tau pathology follows a pattern of age-dependent progression. The 2024 landmark neuropathology study by Sera et al. (PMID: 41865347) examined postmortem brain samples from 98 individuals across four groups[1:1]:
The study focused on three phosphorylated tau (p-tau) epitopes in the frontal cortex: pThr181, pThr217, and pThr231.
A striking finding from Sera et al. (PMID: 41865347) was that despite DSAD cases being younger on average at death, they showed similar pThr181, pThr217, and pThr231 burdens compared to LOAD cases[1:2]. This demonstrates that:
The study found that observed pThr181, pThr217, and pThr231 burdens were higher in DSAD compared to young DS and neurotypical controls[1:3]. This confirms that:
Using generalized additive models, researchers identified a characteristic pattern of age-associated tau phosphorylation increases in DS[1:4]:
| Age (Years) | p-tau Epitope | Pathological Significance |
|---|---|---|
| 40 | pThr231 | First major rise in frontal cortex p-tau |
| 42 | pThr181, pThr217 | Follow pThr231 increase |
This sequence—with pThr231 preceding pThr181 and pThr217—provides a template for understanding biomarker timing in DS and sporadic AD.
Phosphorylation at threonine 231 appears to be the earliest marker of tau pathology in DS, with significant increases beginning around age 40. This epitope is particularly relevant because:
pThr181 increases slightly later than pThr231, around age 42, and is one of the most extensively studied p-tau epitopes in AD. In DS[4]:
pThr217 is emerging as a highly specific marker for AD pathology[5]:
CSF biomarkers in DS provide insight into the temporal sequence of pathology[2:1][3:1]:
| Biomarker | Change in DS | Clinical Relevance |
|---|---|---|
| Aβ42 | Decreased (reflects plaque deposition) | Early marker of Aβ accumulation |
| Total tau (t-tau) | Elevated | Neuronal injury marker |
| p-tau231 | Elevated | Earliest p-tau change |
| p-tau181 | Elevated | Correlates with tau PET |
| p-tau217 | Elevated | Highly specific for AD |
The emergence of ultra-sensitive blood tests has made population screening feasible in DS[4:1][5:1]:
The p-tau epitope pattern in DS-AD has important diagnostic implications:
The unique trajectory of pathology in DS offers a therapeutic window:
Sera et al. Tau phosphorylation across the Down syndrome lifespan (2024). 2024. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Wiseman et al. A checklist for filling the knowledge gaps in Alzheimer's disease (2025). 2025. ↩︎ ↩︎
Bathelt et al. Amyloid pathology in Down syndrome (2023). 2023. ↩︎ ↩︎
Pike et al. Blood p-tau181 as a biomarker in Down syndrome (2024). 2024. ↩︎ ↩︎
Janelidze et al. Plasma p-tau217 for Alzheimer's disease in Down syndrome (2024). 2024. ↩︎ ↩︎